Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for guselkumab (tremfya)

  1. Guselkumab for treating moderately to severely active ulcerative colitis (TA1094)

    Evidence-based recommendations on guselkumab (Tremfya) for treating moderately to severely active ulcerative colitis in adults.

  2. Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)

    Evidence-based recommendations on guselkumab (Tremfya) for previously treated moderately to severely active Crohn's disease.

  3. Guselkumab for treating moderate to severe plaque psoriasis (TA521)

    Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults.

  4. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)

    Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.